
|Articles|July 1, 2004
Gene-directed therapy for AMD on the horizon
Iowa City, IA-The development of gene-directed therapy for common genetic ocular diseases that will be deployable on a population scale rests on coordinated research involving a series of steps. However, judging from progress made so far, such modalities might become clinically available soon, said Edwin M. Stone, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
3
Ophthalmic innovation by the decades: The 2010s
4
AAO 2025: Insights on the PULSAR extension study
5